UA Awarded National Cancer Research Grant
News Feb 06, 2012
The Translational Genomics Research Institute, or TGen, and the University of Arizona have received a three-year, $600,000 grant to study targeted cancer therapies from the National Foundation for Cancer Research, or NFCR.
The grant will enable TGen and the UA to continue its NFCR Center for Targeted Cancer Therapies, or NCTCT, created in 2002, which is dedicated to discovering new therapies to treat pancreatic cancer, the nation's fourth leading cause of cancer death.
The center is co-directed by TGen physician-in-chief Dr. Daniel Von Hoff, one of the nation's top oncologists and one of the world's leading authorities on pancreatic cancer, and by Dr. Laurence Hurley, a renowned medicinal chemist in the field of drug design and development and a professor of medicinal chemistry and the Howard Schaeffer Endowed Chair in Pharmaceutical Sciences in the College of Pharmacy at the UA.
"This NFCR grant should provide renewed hope for pancreatic cancer patients. This should help us move closer to better treatments and hopefully a cure for this devastating disease," said Von Hoff, who began working on the project when he was director of the UA's Arizona Cancer Center in Tucson.
Researchers at NCTCT have developed new therapies that block the growth of pancreatic cancer cells by interfering with the molecules that promote pancreatic cancer cells, an approach called targeted cancer therapy.
"The overall objective of the research is to design and develop novel antitumor agents that will extend the productive lives of patients who have cancer," said Hurley, also a member of the UA Cancer Center and BIO5 Institute.
"Our medicinal chemistry research depends upon a structure-based approach to drug design that is intertwined with clinical oncology programs in cancer therapeutics directed by Dr. Von Hoff."
While traditional chemotherapeutic drugs impair cell division in a general way, targeted therapies specifically kill cancer cells and leave normal cells unharmed, resulting in enhanced cancer-killing power and fewer side effects.
"If we can create the right drug to turn on the right gene to turn off the cancer, that is going to be a whole new approach to treating this disease," said NFCR President Franklin C. Salisbury Jr. "This is 21st Century medicine. Not only do we need to support this research, but the world needs to know that we are on our way to curing cancer."
One specific area of research at NCTCT focuses on the development of agents that target the mutated K-Ras gene, which signals cancer cells to proliferate, migrate and survive.
"The NFCR grant is enabling us to go after a key gene that is the most common abnormal gene in pancreatic cancer. We want to target that gene," Von Hoff said.
Mutations in the K-Ras gene are found in more than 95 percent of pancreatic cancers. These mutations cause K-Ras proteins to be constantly activated. Inhibition of this mutant K-Ras gene should have profound effects on limiting the growth and survival of pancreatic cancer cells.
Von Hoff and Hurley have identified promising compounds that, in laboratory tests, inhibit growth of pancreatic cancer cell lines expressing the mutant K-Ras gene. They hope to advance three new candidate compounds over the next three years.
Besides targeting the mutant K-Ras gene, the center also is using computational methods to extract genomics and pathway information from cancer cells and match each patient with the most effective treatment option available.
Nearly 44,000 Americans were diagnosed with pancreatic cancer in 2011, and more than 37,000 died last year from this aggressive disease, which kills most patients within the first year. The pancreas is a gland behind the stomach that secretes enzymes into the small intestine to help digestion and produce hormones.
There are no early detection methods available, so the cancer usually is not found until its advanced stages.
The National Foundation for Cancer Research is a leading cancer research charity dedicated to funding cancer research and public education relating to cancer prevention, earlier diagnosis, better treatments and, ultimately, a cure for cancer.
The NFCR promotes and facilitates collaboration among scientists to accelerate the pace of discovery from bench to bedside. Since 1973, NFCR has provided more than $288 million in support of discovery-oriented cancer research focused on understanding how and why cells become cancerous, and on public education relating to cancer prevention, detection, and treatment.
NFCR scientists are discovering cancer's molecular mysteries and translating these discoveries into therapies that hold the hope for curing cancer.
The Translational Genomics Research Institute is a Phoenix, Ariz.-based non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes.
TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process.
TGen is affiliated with the Van Andel Research Institute in Grand Rapids, Mich.
A human pluripotent stem cell line has been engineered which contains two ‘suicide genes’ that induce cell death in all but the desired insulin-producing cells. This double fail-safe approach opens the door to creating safe cell-replacement therapies for people living with type 1 diabetes.READ MORE